<DOC>
	<DOCNO>NCT02726386</DOCNO>
	<brief_summary>This multi-center , international , open-label , safety study ND0612 , solution levodopa/carbidopa ( LD/CD ) deliver via pump system continuous SC infusion subject advance Parkinson 's Disease .</brief_summary>
	<brief_title>A Clinical Study Investigating Long Term Safety ND0612 , Solution Levodopa/Carbidopa Administered Continuous Subcutaneous Infusion Subjects With Advanced Parkinson 's Disease</brief_title>
	<detailed_description>This phase open-label safety study conduct approximately 100 subject .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Male female , Parkinson 's disease subject race age 30 85 year . PD diagnosis consistent UK Brain Bank Criteria . Modified Hoehn &amp; Yahr scale `` ON '' state stage â‰¤3 . Taking least 4 doses/day Levodopa ( least 3 doses/day Rytary ) taking , attempted take , least 1 Parkinson 's disease treatment least 30 day previous year . Subjects must stable antiParkinson 's disease medication least 30 day Day 1 . Subjects may prior exposure Sub Cutaneous apomorphine injections/infusion must stop administration least 4 week screen visit . Treatment apomorphine prohibit entire ND0612 treatment period . Must minimum 2 hour `` OFF '' time per day predictable early morning `` OFF '' period estimate subject . Must predictable well define early morning `` OFF '' period good response Levodopa treatment early morning `` OFF '' judgement investigator . Mini Mental State Examination ( MMSE ) score &gt; 26 . No clinically significant medical , psychiatric laboratory abnormality investigator judge would unsafe noncompliant study . Female subject must surgically sterile ( hysterectomy , bilateral oophorectomy , tubal ligation ) , postmenopausal ( defined cessation menses least 1 year ) , willing practice highly effective method contraception . All female participant must nonlactating nonpregnant negative urine pregnancy test Screening Baseline . Female subject childbearing potential must practice highly effective method contraception ( oral contraceptive plus barrier method birth control [ condom contraceptive foam , diaphragms contraceptive jelly ] , intrauterine device , partner vasectomy ) , 1 month enrollment , duration study , 3 month last dose study drug . Willing able administer subcutaneous infusion alone assistance study partner screen period 28 day willing able comply study requirement . For Cohort 1 Cohort 2 , follow exclusion criterion applies : Previously unable tolerate ND0612 and/or experience intolerable adverse drug reaction associate use , regardless dose regimen administer . For Cohort 2 , follow exclusion criterion apply : Atypical secondary parkinsonism . Acute psychosis hallucination past 6 month . Any relevant medical , surgical , psychiatric condition , laboratory value , concomitant medication , opinion Investigator make subject unsuitable study entry potentially unable complete aspect study . Prior neurosurgical procedure Parkinson 's disease , duodopa treatment . Subjects history drug abuse alcoholism within past 12 month . Clinically significant ECG rhythm abnormality . Renal liver dysfunction may alter drug metabolism include : serum creatinine &gt; 1.3 mg/dL , serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2 x upper limit normal ( ULN ) , total serum bilirubin &gt; 2.5 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>